280 related articles for article (PubMed ID: 25053899)
1. Trastuzumab-conjugated liposome-coated fluorescent magnetic nanoparticles to target breast cancer.
Jang M; Yoon YI; Kwon YS; Yoon TJ; Lee HJ; Hwang SI; Yun BL; Kim SM
Korean J Radiol; 2014; 15(4):411-22. PubMed ID: 25053899
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with
Cędrowska E; Pruszyński M; Gawęda W; Żuk M; Krysiński P; Bruchertseifer F; Morgenstern A; Karageorgou MA; Bouziotis P; Bilewicz A
Molecules; 2020 Feb; 25(5):. PubMed ID: 32106568
[TBL] [Abstract][Full Text] [Related]
3. Targeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumab.
Choi WI; Lee JH; Kim JY; Heo SU; Jeong YY; Kim YH; Tae G
Nanomedicine; 2015 Feb; 11(2):359-68. PubMed ID: 25262581
[TBL] [Abstract][Full Text] [Related]
4. Enhanced and selective delivery of enzyme therapy to 9L-glioma tumor via magnetic targeting of PEG-modified, β-glucosidase-conjugated iron oxide nanoparticles.
Zhou J; Zhang J; Gao W
Int J Nanomedicine; 2014; 9():2905-17. PubMed ID: 24959078
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab.
Yousefpour P; Atyabi F; Vasheghani-Farahani E; Movahedi AA; Dinarvand R
Int J Nanomedicine; 2011; 6():1977-90. PubMed ID: 21976974
[TBL] [Abstract][Full Text] [Related]
6. Silica-coated magnetite nanoparticles labeled by nimotuzumab, a humanised monoclonal antibody to epidermal growth factor receptor: preparations, specific targeting and bioimaging.
Ma M; Zhang Y; Gong H; Li F; Gu N
J Nanosci Nanotechnol; 2013 Oct; 13(10):6541-5. PubMed ID: 24245112
[TBL] [Abstract][Full Text] [Related]
7. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI.
Chen TJ; Cheng TH; Chen CY; Hsu SC; Cheng TL; Liu GC; Wang YM
J Biol Inorg Chem; 2009 Feb; 14(2):253-60. PubMed ID: 18975017
[TBL] [Abstract][Full Text] [Related]
8. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.
Truffi M; Colombo M; Sorrentino L; Pandolfi L; Mazzucchelli S; Pappalardo F; Pacini C; Allevi R; Bonizzi A; Corsi F; Prosperi D
Sci Rep; 2018 Apr; 8(1):6563. PubMed ID: 29700387
[TBL] [Abstract][Full Text] [Related]
9. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies.
Lin YL; Tsai NM; Chen CH; Liu YK; Lee CJ; Chan YL; Wang YS; Chang YC; Lin CH; Huang TH; Wang CC; Chi KH; Liao KW
J Nanobiotechnology; 2019 Feb; 17(1):25. PubMed ID: 30728015
[TBL] [Abstract][Full Text] [Related]
10. Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications.
Yallapu MM; Othman SF; Curtis ET; Bauer NA; Chauhan N; Kumar D; Jaggi M; Chauhan SC
Int J Nanomedicine; 2012; 7():1761-79. PubMed ID: 22619526
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies.
Koopaei MN; Dinarvand R; Amini M; Rabbani H; Emami S; Ostad SN; Atyabi F
Int J Nanomedicine; 2011; 6():1903-12. PubMed ID: 21931485
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of doxorubicin by magnetic mesoporous silica nanoparticles armed with mucin-1 aptamer.
Siminzar P; Omidi Y; Golchin A; Aghanejad A; Barar J
J Drug Target; 2020 Jan; 28(1):92-101. PubMed ID: 31062625
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional superparamagnetic nanoparticles conjugated with fluorescein-labeled designed ankyrin repeat protein as an efficient HER2-targeted probe in breast cancer.
Li DL; Tan JE; Tian Y; Huang S; Sun PH; Wang M; Han YJ; Li HS; Wu HB; Zhang XM; Xu YK; Wang QS
Biomaterials; 2017 Dec; 147():86-98. PubMed ID: 28938164
[TBL] [Abstract][Full Text] [Related]
14. Nanohybrid magnetic liposome functionalized with hyaluronic acid for enhanced cellular uptake and near-infrared-triggered drug release.
Nguyen VD; Zheng S; Han J; Le VH; Park JO; Park S
Colloids Surf B Biointerfaces; 2017 Jun; 154():104-114. PubMed ID: 28329728
[TBL] [Abstract][Full Text] [Related]
15. Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer.
Chen H; Wang L; Yu Q; Qian W; Tiwari D; Yi H; Wang AY; Huang J; Yang L; Mao H
Int J Nanomedicine; 2013; 8():3781-94. PubMed ID: 24124366
[TBL] [Abstract][Full Text] [Related]
16. Delivery of tissue plasminogen activator and streptokinase magnetic nanoparticles to target vascular diseases.
Tadayon A; Jamshidi R; Esmaeili A
Int J Pharm; 2015 Nov; 495(1):428-438. PubMed ID: 26363110
[TBL] [Abstract][Full Text] [Related]
17. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
18. One-step detection of circulating tumor cells in ovarian cancer using enhanced fluorescent silica nanoparticles.
Kim JH; Chung HH; Jeong MS; Song MR; Kang KW; Kim JS
Int J Nanomedicine; 2013; 8():2247-57. PubMed ID: 23818781
[TBL] [Abstract][Full Text] [Related]
19. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
[TBL] [Abstract][Full Text] [Related]
20. Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells.
Mu Q; Kievit FM; Kant RJ; Lin G; Jeon M; Zhang M
Nanoscale; 2015 Nov; 7(43):18010-4. PubMed ID: 26469772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
